A European team has used the diabetes drug glibenclamide to block inflammation-induced neurodegeneration in mice. The team plans to test the nonspecific inhibitor of the cationic channel TRPM4 in an investigator-led clinical trial in multiple sclerosis and is looking for pharma partners to develop more specific antagonists of the target.